The rising prevalence of obesity and its associated co-morbidities has become a global healthcare concern. Treating obesity clinically remains a significant challenge. GPR75, a member of the G protein-coupled receptor (GPCR) family, has emerged as a novel target for managing obesity and related metabolic disorders. Studies have demonstrated that the GPR75 signaling pathway can be inhibited by small molecules and antibodies, offering a potential therapeutic strategy for obesity. The GPR75 product may enhance the development of in silico drug discovery efforts targeting obesity and its associated co-morbidities.